Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity

BACKGROUND: Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). We investigated whether crizotinib could influence heart rate (HR)...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cardiooncology
Hlavní autoři: Zhang, Zhushan, Huang, Tai-Qin, Nepliouev, Igor, Zhang, Hengtao, Barnett, Adam S., Rosenberg, Paul B., Ou, Sai-Hong I., Stiber, Jonathan A.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5310672/
https://ncbi.nlm.nih.gov/pubmed/28217366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40959-017-0020-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky